OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s disease and ulcerative colitisYear: 2020
Authors: S. Ben-Horin1, J. Leszczyszyn2, R. Dudkowiak2, A. Lahat3, B. Gawdis-Wojnarska4, A. Pukitis5, M. Horynski6, K. Farkas7, J. Kierkus8, M. Kowalski9, B.D. Ye10, W. Reinisch11, S.J. Lee12, S.H. Kim13, M.R. Kim13, Y.A. Kim13, H.N. Kim14, S. Schreiber15
Created: Thursday, 30 January 2020, 10:12 AM
OP24: Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn’s Disease: Week 48 analyses from the phase 2 GALAXI 1 studyYear: 2022
Source: ECCO'22
Authors: Danese, S.(1);Panaccione, R.(2);Rubin, D.T.(3);Sands, B.E.(4);Reinisch, W.(5);D'Haens, G.(6);Panés, J.(7);Gonzalez, S.(8);Weisel, K.(8);Sahoo, A.(8);Frustaci, M.E.(8);Yang, Z.(8);Sandborn, W.J.(9);Afzali, A.(10);Hisamatsu, T.(11);Andrews, J.M.(12);Feagan, B.(13); on behalf of the GALAXI-1 investigators
Created: Friday, 11 February 2022, 3:52 PM
OP24: Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn’s diseaseYear: 2019
Source: ECCO '19 Copenhagen
Authors: M. Fumery*1, L. Peyrin-biroulet2, S. Nancey3, R. Altwegg4, P. Veyrard5, G. Bouguen6, S. Viennot7, F. Poullenot8, J. Filippi9, A. Buisson10, A. Bozon11, C. Gilletta12, F. Brazier13, L. Pouillon2, B. Flourié14, L. Boivineau4, L. Siproudhis6, D. Laharie8, X. Roblin15, X. Treton11
Created: Friday, 22 February 2019, 9:41 AM
OP24: Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE studyYear: 2021
Source: ECCO'21 Virtual
Authors: Danese, S.(1);Vermeire , S.(2);Zhou, W.(3);Pangan, A.(4);Siffledeen, J.(5);Hébuterne, X.(6);Nakase, H.(7);Higgins, P.(8);Chen, M.H.(9);Sanchez-Gonzalez, Y.(3);Huang, B.(3);Xie, W.(4);Liu, J.(4);Weinreich, M.(4);Pannaccione, R.(10)
Created: Wednesday, 2 June 2021, 4:12 PM
OP24: Neutralising antibody potency against SARS-CoV-2 wild-type and Omicron BA.1 and BA.4/5 variants in infliximab and vedolizumab treated patients with Inflammatory Bowel Disease after three doses of COVID-19 vaccine: a prospective multicentre cohort studyYear: 2023
Source: ECCO’23 Copenhagen
Authors: Liu, Z.(1)*;Le, K.(1);Zhou, X.(1);Alexander, J.(1);Lin, S.(2);Bewshea, C.(2);Chanchlani, N.(2);Nice, R.(3);McDonald, T.(3);Lamb, C.(4);Sebastian, S.(5);Kok, K.(6);Lees, C.(7);Hart, A.(1);Pollok, R.(8);Boyton, R.(9);Altmann, D.(10);Pollock, K.(9);Goodhand, J.(2);Kennedy, N.(2);Ahmad, T.(2);Powell, N.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP25: Efficacy of filgotinib in patients with Ulcerative Colitis by line of therapy in the phase 2b/3 SELECTION trialYear: 2021
Source: ECCO'21 Virtual
Authors: Peyrin-Biroulet, L.(1);Dotan, I.(2,3);Hibi, T.(4);Taliadouros, V.(5);Oortwijn, A.(5);Zhao, S.(6);Zhang, J.(6);Hsieh, J.(6);Feagan, B.(7,8)
Created: Wednesday, 2 June 2021, 4:12 PM
OP25: Patients with moderate to severe Crohn’s Disease with and without prior biologic failure demonstrate improved endoscopic outcomes with risankizumab: Results from phase 3 induction and maintenance trialsYear: 2022
Source: ECCO'22
Authors: Ferrante, M.(1);Cao, Q.(2);Fujii, T.(3);Rausch, A.(4);Neimark, E.(5);Song, A.(6);Wallace, K.(6);Kligys, K.(7);Zhou, Q.(8);Kalabic, J.(9);Feagan, B.G.(10);
Created: Friday, 11 February 2022, 3:52 PM
OP25: Prevalence of IBD in the Netherlands: development and validation of machine learning models for administrative dataYear: 2023
Source: ECCO’23 Copenhagen
Authors: Van Linschoten, R.(1,2,3)*;van Leeuwen, N.(2);Hazelzet, J.A.(2);van der Woude, C.J.(3);van Noord, D.(4);West, R.L.(4);
Created: Friday, 14 July 2023, 10:43 AM
OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s diseaseYear: 2019
Source: ECCO '19 Copenhagen
Authors: E. Dreesen*1, F. Baert2, D. Laharie3, P. Bossuyt4, Y. Bouhnik5, A. Buisson6, G. Lambrecht7, E. Louis8, B. Oldenburg9, B. Pariente10, M. Pierik11, C. J. van der Woude12, G. D’Haens13, S. Vermeire14,15, A. Gils1
Created: Friday, 22 February 2019, 9:41 AM
OP26 The first real-life multicentre prospective validation study of the electronic chromoendoscopy score (Paddington International Virtual ChromoendoScopy ScOre) and its outcome in ulcerative colitisYear: 2020
Authors: M. Iacucci1, S.C. Smith2, A. Bazarova2, U.N. Shivaji1, P. Bhandari3, R. Cannatelli2, M. Daperno4, J.G. Ferraz5, M. Goetz6, X. Gui7, B. Hayee8, G. De Hertogh9, M. Lazarev10, J. Li11, O.M. Nardone2, V. Occhipinti12, R. Panaccione5, A. Parra-Blanco13, L. Pastorelli12, T. Rath14, G. Tontini15, M. Vieth16, V. Villanacci17, D. Zardo18, R. Kiesslich19, R. Bisschops20, S. Ghosh1
Created: Thursday, 30 January 2020, 10:12 AM
OP26: Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 studyYear: 2022
Source: ECCO'22
Authors: D'Haens, G.(1);Kobayashi, T.(2);Morris, N.(3);Lissoos, T.(3);Hoover, A.(3);Li, X.(3);Arora, V.(3);Milch, C.(3);Sandborn, W.J.(4);Sands, B.E.(5);
Created: Friday, 11 February 2022, 3:52 PM
OP26: Impact of telemonitoring with TECCU on the management of Inflammatory Bowel Disease in Spain: a GETECCU clinical trialYear: 2023
Source: ECCO’23 Copenhagen
Authors: Aguas Peris, M.(1,2)*;Del Hoyo, J.(1,2);Vicente, R.(3,4);Barreiro-de Acosta, M.(5);Melcarne, L.(6);Hernández-Camba, A.(7);Alfambra, E.(8,9);Madero, L.(10,11);Sicilia, B.(12);Chaparro, M.(13,14,15,16);Martín-Arranz, M.D.(14,17,18);Pajares, R.(19);Mesonero, F.(20);Mañosa, M.(16,21);Martínez, P.(22);Chacón , S.(23);Tosca, J.(24);Marín, S.(25,26);Sanromán, L.(27,28,29,30);Calvo, M.(31);Monfort, D.(32);Saiz, E.(33);Zabana, Y.(16,34);Guerra, I.(35);Varela, P.(36);Faubel, R.(37,38,39);Corsino, P.(3,4);Porto-Silva, S.(5);Brunet, E.(6);Gutiérrez, A.(10,11,16);Nos, P.(1,2);
Created: Friday, 14 July 2023, 10:43 AM
OP26: Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS studyYear: 2019
Source: ECCO '19 Copenhagen
Authors: S. Vermeire1, J-F. Colombel2, B. G. Feagan3, W. J. Sandborn4, B. E. Sands2, S. Danese5, G. D’Haens6, R. Panaccione7, D. T. Rubin8, I. Shafran9, A. Parfionovas10, R. Rogers*10, R. A. Lirio10, E. V. LoftusJr11
Created: Friday, 22 February 2019, 9:41 AM
OP26: Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studiesYear: 2021
Source: ECCO'21 Virtual
Authors: Schreiber , S.W.(1);Ferrante , M.(2);Panaccione , R.(3);Colombel , J.F.(4);Hisamatsu , T.(5);Lim , A.(6);Lindsay , J.O.(7);Rubin , D.T.(8);Sandborn , W.J.(9);Neimark , E.(10);Song , A.P.(10);Liao , X.(10);Feng , T.(10);Berg , S.(10);Wallace , K.(10);D’Haens , G.R.(11)
Created: Wednesday, 2 June 2021, 4:12 PM
OP27 Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s disease: Final results from the Phase 2 open-label extension studyYear: 2020
Authors: M. Ferrante1, B.G. Feagan2, J. Panés3, F. Baert4, E. Louis5, O. Dewit6, A. Kaser7, W.R. Duan8, D. Gustafson9, X. Liao10, K. Wallace9, J. Kalabic11, G.R. D’Haens12
Created: Thursday, 30 January 2020, 10:12 AM
OP27: A Phase 1 Study Evaluating the Bioequivalence of the Proposed Commercial and Clinical Formulations of Etrasimod 2mg, and the Effect of Food on the Pharmacokinetics of the Proposed Commercial Formulation in Healthy VolunteersYear: 2022
Source: ECCO'22
Authors: Lee, C.(1);Ramaiya, A.(1);Tang , Y.(1);Sapone, A.(2);Shan , K.(3);Randle, A.(4);Grundy, J.(1);
Created: Friday, 11 February 2022, 3:52 PM
OP27: Benefits of paediatric to adult transition program in Inflammatory Bowel Disease: The BUTTERFLY study of GETECCUYear: 2023
Source: ECCO’23 Copenhagen
Authors: Rubín De Célix, C.(1)*;Martín de Carpi, J.(2);Pujol, G.(2);Palomino, L.(3);Velasco, M.(3);Martín-Masot, R.(4);Navas-López, V.M.(4);Ricart, E.(5);Casanova, M.J.(1);Rodríguez Martínez, A.(6);Leo, E.(7);Alcaraz, A.(8);Mañosa, M.(9);Hernández, V.(10);Fernández, R.(10);Sánchez, C.(11);Menchén, L.(12);Mesonero, F.(13);Barreiro-De Acosta, M.(14);Martinon, N.(15);Tejido Sandoval, C.(16);Rendo Vázquez, A.(17);Corsino, P.(18);Vicente, R.(18);Hernández-Camba, A.(19);Alberto Alonso, J.R.(20);Alonso-Abreu, I.(21);Castro Millán, A.M.(22);Peries Reverter, L.(23);Castro, B.(24);Fernández-Salgado, E.(25);Busto Cuiñas, M.M.(26);Benítez, J.M.(27);Madero, L.(28);Clemente, F.(29);Riestra, S.(30);Jiménez-Treviño, S.(31);Boscá, M.(32);Chaparro, M.(1);Gisbert, J.P.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP27: Has been withdrawnYear: 2021
Source: ECCO'21 Virtual
Authors: Has been withdrawn
Created: Wednesday, 2 June 2021, 4:12 PM
OP27: High-dimensional mass cytometry reveals the immune cell landscape in inflammatory bowel diseaseYear: 2019
Source: ECCO '19 Copenhagen
Authors: V. van Unen1, N. Li1, T. Abdelaal2,3, Y. Kooy-Winkelaar1, L. Ouboter*1,4, G. Beyrend1, T. Höllt3,6, L. Mearin7, A. Witte8, H. Escher9, B. Lelieveldt10,11, A. van der Meulen - de Jong4, F. Koning1
Created: Friday, 22 February 2019, 9:41 AM